cd40 ligand

Recombinant proteinexperimental

CD154, also called CD40 ligand or CD40L, is a protein that is primarily expressed on activated T cells and is a member of the TNF superfamily of molecules. It binds to CD40 on antigen-presenting cells (APC), which leads to many effects depending on the target cell type. In total CD40L has three binding partners: CD40, α5β1 integrin and integrin αIIbβ3. CD154 acts as a costimulatory molecule and is particularly important on a subset of T cells called T follicular helper cells. On TFH cells, CD154 promotes B cell maturation and function by engaging CD40 on the B cell surface and therefore facilitating cell-cell communication. A defect in this gene results in an inability to undergo immunoglobulin class switching and is associated with hyper IgM syndrome. Absence of CD154 also stops the formation of germinal centers and therefore prohibits antibody affinity maturation, an important process in the adaptive immune system. — Wikipedia

Clinical trial activity

6 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started Dec 23, 1996 (NCT00001564)

Timeline

1990s

  1. Jan 1, 1996

    Earliest Phase 2 Sponsor(trial)

2000s

  1. Jan 1, 2001

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • cd40 ligand
  • recombinant cd40-ligand

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00224354Phase 1Sep 1, 2005Baylor University, Methodist Cancer Center, Houston, Texas
NCT00053391Phase 1/Phase 2 (Phase 2)Oct 1, 2002University of Erlangen-Nuremberg
NCT00056134Phase 1/Phase 2 (Phase 2)Oct 1, 2002University of Erlangen-Nuremberg
NCT00020540Phase 1Mar 1, 2001National Cancer Institute (NCI), National Institutes of Health (NIH)
NCT00006113Phase 2Jun 1, 1999National Cancer Institute (NCI), University of Southern California
NCT00001564Phase 2Dec 23, 1996National Cancer Institute (NCI)
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government3221996
University of Erlangen-NurembergAcademic/Hospital2212002
Baylor UniversityAcademic/Hospital1112005
Methodist Cancer Center, Houston, TexasAcademic/Hospital1012005
National Institutes of Health (NIH)Government1012001
University of Southern CaliforniaAcademic/Hospital1111999
6 organizations
Page 1 / 1